Grifols, S.A. (BME:GRF)
Spain
· Delayed Price · Currency is EUR | Market Cap | 5.67B |
| Revenue (ttm) | 7.21B |
| Net Income (ttm) | 156.92M |
| Shares Out | 680.41M |
| EPS (ttm) | 0.23 |
| PE Ratio | 39.65 |
| Forward PE | 11.61 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,196,682 |
| Average Volume | 2,907,189 |
| Open | 9.28 |
| Previous Close | 9.19 |
| Day's Range | 9.10 - 9.28 |
| 52-Week Range | 7.77 - 11.35 |
| Beta | 0.69 |
| RSI | 41.26 |
| Earnings Date | Feb 28, 2025 |
About Grifols
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A an... [Read more]
Financial Performance
In 2024, Grifols's revenue was 7.21 billion, an increase of 9.41% compared to the previous year's 6.59 billion. Earnings were 156.92 million, an increase of 270.81%.
Financial StatementsNews
Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale
Grifols expects to boost revenue and free cash flow, shares soar
Spanish drugmaker Grifols said on Thursday it expects its revenue, core earnings and free cash flow to grow significantly in the coming years as it aims to leave behind a tumultuous 2024 when it lost ...
Grifols SA (GIFLF) (Q4 2024) Earnings Call Highlights: Record Revenues and Strategic ...
Grifols SA (GIFLF) (Q4 2024) Earnings Call Highlights: Record Revenues and Strategic Advancements Amid Challenges
Full Year 2024 Grifols SA Earnings Call Transcript
Full Year 2024 Grifols SA Earnings Call Transcript
Grifols' sales rise over 10% in 2024, above target
Spanish drugmaker Grifols reported on Wednesday a net profit of 157 million euros ($165.02 million) for 2024 on revenues of 7.21 billion euros, up 10.2% from a year earlier and above its target for 7%...
Permian Investment Partners, LP Increases Stake in Grifols SA
Permian Investment Partners, LP Increases Stake in Grifols SA
Blood Plasma Derivatives Market Insights and Forecast 2025-2030 - Grifols, SK Plasma, and Fusion Health Care Lead the Competition
Rising Incidence of Hemophilia, Immunological Disorders, and the Growing Number of Surgical Procedures Worldwide is Driving Growth, at a CAGR of ~9% Rising Incidence of Hemophilia, Immunological Disor...
Grifols falls as Spanish regulator mulls sanctions against directors
Grifols SA (GRFS) Partners with Michael J. Fox Foundation to Advance Parkinson's Disease Research
Grifols SA (GRFS) Partners with Michael J. Fox Foundation to Advance Parkinson's Disease Research
Grifols Pioneers High-Tech Analysis of Plasma Bank to Detect Early Signs of Parkinson's Disease
BARCELONA, Spain, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced it h...
Mason Capital complains about Grifols' transparency to Spanish regulator
U.S.-based investment fund Mason Capital said on Monday it had sent a letter to Spain's stock market regulator CNMV demanding more transparency from the embattled pharmaceutical company Grifols.
Mason Capital Management Sends Letter to Spanish National Securities Market Commission Regarding Lack of Transparency by Grifols
NEW YORK--(BUSINESS WIRE)--Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 2.5% of Grifols S.A. (“Grifols” or the “Company”) (BME: G...
Short Seller Gotham Asks Judge to Toss Grifols Defamation Suit
US short seller Gotham City Research asked a judge in New York to dismiss a lawsuit accusing it of conspiring to drive down shares in Grifols SA.
Grifols, S.A. 2024 Q3 - Results - Earnings Call Presentation
Grifols’ Annus Horribilis Has Analysts and Short Sellers Divided
Spanish drugmaker Grifols SA is poised for its worst year on record, but some analysts aren’t ready yet to give up on a stock that’s been a favorite target of short sellers.
Grifols Seeks to Calm Investors With €1.3 Billion Debt Placement
Grifols SA raised €1.3 billion ($1.4 billion) in a private debt placement, as the Spanish drugmaker seeks to reassure investors about its ability to manage borrowings.
Flat Footed Calls for Prompt Governance Overhaul at Grifols
BARCELONA, Spain--(BUSINESS WIRE)--Flat Footed LLC is the investment manager for FF Hybrid LP, Flat Footed Series LLC - Fund 3, and GP Recovery Fund LLC (collectively, with Flat Footed LLC, “Flat Foot...
Grifols Names Two New Board Members in Win for Hedge Fund Mason
Grifols SA, the drugmaker reeling from a short-seller attack earlier this year, named two new board members, as it faces pressure from a group of small shareholders led by hedge fund Mason Capital Man...
Spain's market regulator sees signs of manipulation in Grifols-Gotham dispute
The outgoing head of Spain's stock market regulator CNMV, Rodrigo Buenaventura, told reporters on Thursday that there were signs of possible market manipulation in the dispute between short seller Got...
SEC Drops Probe Into Gotham Over Report on Grifols’ Accounts
The US dropped its investigation into General Industrial Partners LLP, the parent company of Gotham City Research, which accused drug maker Grifols SA of deceptive accounting earlier this year.
The High-Powered Lawyer Behind the Grifols Group’s Rise and Fall
For hedge fund Mason Capital Management LLC, much of what ails Grifols SA can be laid at the door of one man: Tomas Daga. But for the drugmaker, Daga is someone who’s helped transform the once-tiny Sp...
Mason Capital Management Requests Immediate Disclosure of Important Information Regarding Conflicted Grifols Director Tomas Daga
NEW YORK--(BUSINESS WIRE)--Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols S.A. (“Grifols” or the “Company”) (BME: G...
Statement From Araoz y Rueda on Behalf of Certain Institutional Investors in Grifols
MADRID--(BUSINESS WIRE)--Law firm Araoz y Rueda has been independently engaged by several international and Spanish institutions (the “Clients”) holding in aggregate 5.65% of A shares and 3.88% of B s...
Grifols Shareholder Mason Capital Calls for Board to Be Replaced
Mason Capital Management LLC’s Kenneth M Garschina said he wants Grifols SA’s board replaced.
Key deals this week: EnLink Midstream, Peabody, StoneCo, UniCredit and more
Stay updated on recent acquisitions in the financial sector with news on Grifols, Summit Materials, UniCredit, Peabody, and more.